FGF21 and metabolic dysfunction-associated steatohepatitis: The efficacy and safety of the FGF21 analogue pegbelfermin has been evaluated in two phase 2b clinical study in patients with NASH and stage 3 fibrosis (FALCON1, ClinicalTrials.gov Identifier NCT03486899) and patients with compensated NASH cirrhosis (FALCON2, ClinicalTrials.gov Identifier NCT03486912) [28].